Incyte/$INCY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Ticker

$INCY
Sector
Primary listing

Employees

2,617

Incyte Metrics

BasicAdvanced
$17B
19.91
$4.37
0.72
-

What the Analysts think about Incyte

Analyst ratings (Buy, Hold, Sell) for Incyte stock.

Bulls say / Bears say

Incyte entered a $10 million upfront collaboration with Syros Pharmaceuticals focused on discovering novel myeloproliferative neoplasm targets, securing exclusive rights and potential milestone payments up to $169 million plus royalties, significantly bolstering its core MPN pipeline (Reuters).
Total Q2 2025 product revenues rose 17% year-over-year to $1 059 million, driven by Jakafi’s 8% growth and Opzelura’s 35% jump, underscoring robust demand and operational execution (Nasdaq).
Bill Meury’s appointment as President and CEO on June 26, 2025 brings proven leadership continuity following Hervé Hoppenot’s retirement, positioning Incyte for its next growth phase (Nasdaq).
Adjusted R&D expenses (excluding acquisition costs) increased 8% year-over-year to $455.6 million in Q2 2025, reflecting elevated development spending that may pressure margins (Nasdaq).
Adjusted SG&A expenses rose 16% year-over-year to $304.8 million, driven by higher legal costs related to the Novartis contract dispute settlement, placing further strain on profitability (Nasdaq).
Key pipeline asset INCA033989 remains in Phase 1 with pivotal data not anticipated until the second half of 2025, highlighting ongoing binary risk before potential commercial upside (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

Incyte Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Incyte Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INCY

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs